BiomX, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Tables)

6 Months Ended

Jun. 30, 2021

	Six Months Ended June 30,
	2021		2020
Underlying value of Common Stock ($)		7.02		5.59-6.21
Exercise price ($)		7.02		5.59-6.21
Expected volatility (%)		85.0		85.0
Term of the option (years)		6.11		6.25
Risk-free interest rate (%)		1.17		0.37-0.52

	For the Six Months Ended June 30, 2021
	Number of Options			Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at the beginning of period		3,569,766			3.12		12,338
Granted		985,530			7.02
Forfeited		(89,354	)		4.15
Exercised		(67,892	)		1.49
Outstanding at the end of period		4,398,050			4.00		9,424
Exercisable at the end of period		2,231,281
Weighted average remaining contractual life of outstanding options – years as of June 30, 2021		7.62

	Six Months Ended June 30,
	2021		2020
Research and development expenses, net		958		502
General and administrative		667		512
		1,625		1,014

	Three Months Ended June 30,
	2021		2020
Research and development expenses, net		627		310
General and administrative		468		367
		1,095		677

Warrant

Issuance Date

Expiration
Date

Exercise
Price
Per Share

Number of
Shares of
Common Stock
Underlying
Warrants

Private Warrants issued to Yeda (see 1 below)

May 11, 2017

May 11, 2025

)

Private Warrants issued to scientific founders (see 2 below)

November 27, 2017

2,974